DK3250600T3 - Behandling af autoimmune lidelser med cd154-antistoffer - Google Patents
Behandling af autoimmune lidelser med cd154-antistoffer Download PDFInfo
- Publication number
- DK3250600T3 DK3250600T3 DK15719675.9T DK15719675T DK3250600T3 DK 3250600 T3 DK3250600 T3 DK 3250600T3 DK 15719675 T DK15719675 T DK 15719675T DK 3250600 T3 DK3250600 T3 DK 3250600T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibodies
- treatment
- autoimmune diseases
- autoimmune
- diseases
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1501613.2A GB201501613D0 (en) | 2015-01-30 | 2015-01-30 | Treatment of autoimmune disorders with CD154 antibodies |
| PCT/EP2015/059095 WO2016119909A1 (en) | 2015-01-30 | 2015-04-27 | Treatment of autoimmune disorders with cd154 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3250600T3 true DK3250600T3 (da) | 2020-06-08 |
Family
ID=52705552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15719675.9T DK3250600T3 (da) | 2015-01-30 | 2015-04-27 | Behandling af autoimmune lidelser med cd154-antistoffer |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20180022812A1 (da) |
| EP (2) | EP3744735A1 (da) |
| KR (1) | KR102543877B1 (da) |
| CN (1) | CN107206075A (da) |
| AU (2) | AU2015379642B2 (da) |
| CA (1) | CA2975336C (da) |
| CY (1) | CY1123116T1 (da) |
| DK (1) | DK3250600T3 (da) |
| ES (1) | ES2802982T3 (da) |
| GB (1) | GB201501613D0 (da) |
| HR (1) | HRP20201013T1 (da) |
| HU (1) | HUE050024T2 (da) |
| LT (1) | LT3250600T (da) |
| PL (1) | PL3250600T3 (da) |
| PT (1) | PT3250600T (da) |
| RS (1) | RS60575B1 (da) |
| RU (1) | RU2695443C2 (da) |
| SI (1) | SI3250600T1 (da) |
| WO (1) | WO2016119909A1 (da) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2852056C (en) | 2011-03-11 | 2021-08-10 | Beth Israel Deaconess Medical Center, Inc. | Anti-cd40 antibodies and uses thereof |
| AU2016315873B2 (en) | 2015-09-04 | 2022-08-18 | Primatope Therapeutics Inc. | Humanized anti-CD40 antibodies and uses thereof |
| WO2017148904A1 (en) * | 2016-02-29 | 2017-09-08 | Franz Grus | Predictive markers useful in the treatment of wet age-related macular degeneration |
| CN112770774A (zh) * | 2018-09-24 | 2021-05-07 | 詹森生物科技公司 | 提供安全施用抗cd154抗体的方法 |
| CN114895041A (zh) * | 2021-07-01 | 2022-08-12 | 浙江大学 | 一种检测抗蛋白酶体亚基α1-IgG抗体的试剂盒 |
| AR127813A1 (es) * | 2021-12-01 | 2024-02-28 | UCB Biopharma SRL | FORMULACIONES FARMACEUTICAS QUE COMRENDEN Fab-PEG |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| AU8867501A (en) * | 2000-09-01 | 2002-03-13 | Biogen Inc | Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| JP5721951B2 (ja) | 2007-03-22 | 2015-05-20 | バイオジェン アイデック マサチューセッツ インコーポレイテッド | 抗体、抗体誘導体、および抗体断片を含む、ｃｄ１５４に特異的に結合する結合タンパク質ならびにその使用 |
| ES2650267T3 (es) * | 2008-12-05 | 2018-01-17 | Als Therapy Development Institute | Método para el tratamiento de enfermedades neurodegenerativas |
| AR083847A1 (es) * | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| JP6211513B2 (ja) | 2011-04-26 | 2017-10-11 | ジェネンテック， インコーポレイテッド | 自己免疫疾患の治療のための組成物及び方法 |
-
2015
- 2015-01-30 GB GBGB1501613.2A patent/GB201501613D0/en not_active Ceased
- 2015-04-27 HU HUE15719675A patent/HUE050024T2/hu unknown
- 2015-04-27 LT LTEP15719675.9T patent/LT3250600T/lt unknown
- 2015-04-27 DK DK15719675.9T patent/DK3250600T3/da active
- 2015-04-27 PT PT157196759T patent/PT3250600T/pt unknown
- 2015-04-27 RU RU2017130464A patent/RU2695443C2/ru active
- 2015-04-27 EP EP20172402.8A patent/EP3744735A1/en active Pending
- 2015-04-27 US US15/547,223 patent/US20180022812A1/en not_active Abandoned
- 2015-04-27 WO PCT/EP2015/059095 patent/WO2016119909A1/en active Application Filing
- 2015-04-27 CN CN201580074799.1A patent/CN107206075A/zh active Pending
- 2015-04-27 CA CA2975336A patent/CA2975336C/en active Active
- 2015-04-27 ES ES15719675T patent/ES2802982T3/es active Active
- 2015-04-27 KR KR1020177024036A patent/KR102543877B1/ko active IP Right Grant
- 2015-04-27 EP EP15719675.9A patent/EP3250600B1/en active Active
- 2015-04-27 RS RS20200831A patent/RS60575B1/sr unknown
- 2015-04-27 SI SI201531299T patent/SI3250600T1/sl unknown
- 2015-04-27 PL PL15719675T patent/PL3250600T3/pl unknown
- 2015-04-27 AU AU2015379642A patent/AU2015379642B2/en active Active
-
2020
- 2020-06-26 HR HRP20201013TT patent/HRP20201013T1/hr unknown
- 2020-07-10 CY CY20201100635T patent/CY1123116T1/el unknown
-
2021
- 2021-06-29 US US17/361,393 patent/US11884737B2/en active Active
-
2022
- 2022-01-19 AU AU2022200347A patent/AU2022200347A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2695443C2 (ru) | 2019-07-23 |
| GB201501613D0 (en) | 2015-03-18 |
| AU2022200347A1 (en) | 2022-02-17 |
| RU2017130464A (ru) | 2019-02-28 |
| CA2975336A1 (en) | 2016-08-04 |
| CN107206075A (zh) | 2017-09-26 |
| US11884737B2 (en) | 2024-01-30 |
| ES2802982T3 (es) | 2021-01-22 |
| CY1123116T1 (el) | 2021-10-29 |
| SI3250600T1 (sl) | 2020-09-30 |
| AU2015379642B2 (en) | 2021-11-04 |
| EP3250600A1 (en) | 2017-12-06 |
| EP3250600B1 (en) | 2020-05-06 |
| LT3250600T (lt) | 2020-07-27 |
| PT3250600T (pt) | 2020-06-17 |
| RS60575B1 (sr) | 2020-08-31 |
| KR102543877B1 (ko) | 2023-06-14 |
| EP3744735A1 (en) | 2020-12-02 |
| WO2016119909A1 (en) | 2016-08-04 |
| AU2015379642A1 (en) | 2017-07-27 |
| HUE050024T2 (hu) | 2020-11-30 |
| NZ733454A (en) | 2023-12-22 |
| US20180022812A1 (en) | 2018-01-25 |
| PL3250600T3 (pl) | 2020-09-21 |
| RU2017130464A3 (da) | 2019-02-28 |
| CA2975336C (en) | 2022-10-18 |
| KR20170106476A (ko) | 2017-09-20 |
| HRP20201013T1 (hr) | 2020-10-16 |
| US20210324095A1 (en) | 2021-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3302565T3 (da) | Faste doseringsformer af palbociclib | |
| DK3390441T3 (da) | Antistoffer til neutralisering af human immundefekt virus | |
| DK3253865T3 (da) | Fremgangsmåder til forbedring af virkningen af terapeutiske immunceller | |
| DK3212233T3 (da) | Kombinationsterapi til behandling af sygdom | |
| DK3851537T3 (da) | Behandling af hyperbilirubinæmi | |
| DK3468997T3 (da) | Behandling af IgG4-relaterede sygdomme med anti-CD9-antistoffer med tværbinding til CD32B | |
| DK3244948T3 (da) | Bestemmelse af medikamentdosis | |
| DK3390390T3 (da) | Bipyrazolylderivater egnede til behandling af autoimmunsygdomme | |
| DK3137169T3 (da) | Hæmmere af lysin-specifik demethylase-1 | |
| DK3450553T3 (da) | Mrna-terapi til behandling af øjensygdomme | |
| DK3117310T3 (da) | Håndtering af behandling associeret med valgte arkitektoniske indretninger | |
| DK3137504T3 (da) | Antistofbinding til fcrn til behandling af autoimmunsygdomme | |
| DK3125875T3 (da) | Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande | |
| DK3099298T3 (da) | Kombinationsterapier med zidovudin til behandling af mikrobielle infektioner | |
| DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
| DK3609529T3 (da) | Rna til behandling af autoimmune sygdomme | |
| DK3865484T3 (da) | Pde9-hæmmer med imidazopyrazinon-rygrad til behandling af perifere sygdomme | |
| DK3182996T3 (da) | Fremgangsmåder til behandling af myelomatose med immunmodulatoriske forbindelser i kombination med antistoffer | |
| DK3297653T3 (da) | Behandling af postbariatrisk hypoglykæmi med glp-1-antagonister | |
| DK3307267T3 (da) | Behandling af multipel sklerose | |
| DK3612208T5 (da) | Coversin til behandlingen af autoimmune sygdomme med blisterdannelse | |
| DK3250600T3 (da) | Behandling af autoimmune lidelser med cd154-antistoffer | |
| DK3166628T3 (da) | Terapeutisk anvendelse af knoglemorfogenetiske proteiner | |
| DK3548061T3 (da) | Behandling af neurologiske sygdomme | |
| DK3237621T3 (da) | Varianter af human alpha-galactosidase |